Clinical outcome data for off-label medications: The more the better

Auteurs-es

  • Karen J. Psooy University of Manitoba Winnipeg Children's Hospital

DOI :

https://doi.org/10.5489/cuaj.2058

Mots-clés :

n/a

Téléchargements

Les données relatives au téléchargement ne sont pas encore disponibles.

Biographie de l'auteur-e

Karen J. Psooy, University of Manitoba Winnipeg Children's Hospital

Associate Professor, University of Manitoba

Section Head, Urology

Références

Nadeau G, Schröder A, Moore K, Genois L, Lamontagne P, Hamel M, Pellerin È, Bolduc S. Long-term use of solifenacin in pediatric patients with overactive bladder: extension of a prospective open-label study. Can Urol Assoc J 2014;XX:XX.

Bolduc S, Moore K, Nadeau G, Lebel S, Lamontagne P, Hamel M. Prospective open label study of solifenacin for overactive bladder in children. J Urol 2010;184(4 Suppl):1668-1673.

Téléchargements

Publié-e

2014-04-14

Comment citer

Psooy, K. J. (2014). Clinical outcome data for off-label medications: The more the better. Canadian Urological Association Journal, 8(3-4), 124. https://doi.org/10.5489/cuaj.2058

Numéro

Rubrique

Commentary